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We retrospectively reviewed the charts of all of our patients with a history of partial seizures, with and without secondarily
generalisation, who received levetiracetam (LEV; Keppra®) for treatment of their seizures during the years 2000–2002. Forty-five
patients were identified, 13 of whom began LEV as first line therapy. Eleven patients continued on LEV for at least 6 months;
six of whom became seizure free and five had >50% reduction in their seizures. The remaining two patients discontinued LEV
because of adverse effects. LEV monotherapy can be effective and well tolerated in adults with new onset seizures. A prospective,
large, double-blind monotherapy study for newly diagnosed patients is needed to confirm this finding.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Levetiracetam (LEV) is a novel antiepileptic drug
(AED) that received FDA approval in November
1999 as adjunctive treatment for adults with partial
onset seizures. Its effectiveness was established in
three multicentre, well-controlled pivotal drug study
trials1–3. In addition, LEV is well tolerated with a
favourable pharmacokinetic profile that includes min-
imal protein binding, lack of hepatic metabolism and
twice a day dosing4. These features and others make
it ideal for use as monotherapy.
In a European multicentre placebo-controlled,
responder-selected monotherapy study, conversion to
LEV monotherapy was successful in patients with
refractory partial epilepsy3. However, the effective-
ness of LEV as a single agent in newly diagnosed
epilepsy patients is currently unknown. In this study,
we wished to review our experience with LEV in
newly diagnosed epilepsy patients.
METHODS
We retrospectively reviewed the charts of our patients
who were diagnosed with epilepsy after having two
unprovoked seizures during the years 2000–2002. All
patients underwent a thorough workup that included
MRI and EEG. We identified patients who received
LEV as monotherapy or as adjunctive treatment.
From this cohort of patients, we identified 13 patients
with newly diagnosed epilepsy. Ten of these patients
were never exposed to an AED, while three briefly
received an AED (less than 2 weeks), but had to
discontinue because of poor tolerance or side-effects
(n = 3).
We reviewed patients’ demographic data, diagnos-
tic evaluation for epilepsy, seizure types and seizure
frequency prior to and following initiation of LEV
monotherapy. All patients had follow-up visits at reg-
ular intervals every 2 months, or at shorter intervals if
medically necessary. No patients failed to follow-up
while on LEV. All patients had their LEV dose titrated
from a starting dose of 500 mg day−1 in two divided
doses up to a maximum tolerated dose no greater than
5000 mg day−1. For elderly patients, the dose was
titrated up to 2000 mg day−1 or seizure freedom. We
compared baseline seizure counts from the 2 months
prior to initiation of LEV treatment to seizure counts
at 6 months of follow-up after LEV was started and
maintained as therapy. Seizure frequency was de-
termined using a seizure diary completed by each
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patient or his or her caregivers, which is standard
practice in our clinic. Adverse events (AEs) while
on LEV were also noted at each clinic visit. This
information was kept in a computerised data sys-
tem that was maintained up-to-date by the co-author
(CT).
RESULTS
We identified 13 female patients, ages 17–66 (mean
40.3), with a history of partial seizures with and with-
out secondarily generalisation. (Although our clinic
includes males and females, no males met the inclu-
sion criteria for this study.) The duration of epilepsy
ranged from 1 to 52 years (mean 5.4 years, median
2 years). One patient had undiagnosed seizures for
52 years prior to LEV treatment. Three of these pa-
tients had liver disease and consequently wished to
avoid AEDs that required hepatic metabolism. The re-
maining nine patients chose to start LEV because of
its favourable pharmacokinetic and side-effect profile.
Five patients had an identifiable cause to their seizures;
two secondary to head trauma, two secondary to stroke
and one secondary to cortical dysplasia. Characteris-
tics and demographics of our group of patients are
summarised in Table 1.
Of the 13 patients, eleven (84%) continued on LEV
monotherapy for at least 6 months. Two patients
discontinued therapy within 2 weeks after LEV was
started at dosages less than 500 mg day−1 because of
side-effects (irritability). Of the 11 patients who were
maintained on LEV as first line therapy for at least
6 months, 6 became seizure free and 5 patients had
>50% reduction in their seizures (Fig. 1).
Three patients reported being nervous (irritable)
within 2 weeks after starting on LEV as a single agent
on 500 mg day−1 of LEV. Two patients discontinued
LEV, while the third patient was able to continue
on LEV when her complaints decreased after the
first month of therapy. Another patient reported be-
ing dizzy within days after starting LEV but was
able to continue on LEV. No other major AEs were
reported.
Table 1: Demographics and characteristics of the LEV
monotherapy group.
Variable LEV (n = 13)
Mean age (years; SD) 40.3 (17.9)
Gender (% male/female) 0/100
Age at epilepsy onset (years; SD) 36.08 (19.08)
Mean duration of epilepsy (years; SD) 5.4 (13.9)
Cause of epilepsy (% unknown) 61
Mean seizures frequency (n per month) 1.56
Mean LEV dosages (mg day−1) 1750
Fig. 1: Effect of LEV monotherapy on seizure frequency.
Each bar represents the percentage of patients achieving
more than 50% reduction, 100% reduction and the patients
who discontinued treatment.
DISCUSSION
This study suggests that LEV monotherapy can be ef-
fective in treating newly diagnosed epilepsy patients.
Forty-six percent of our patients became seizure free
after starting LEV and 38% had more than a 50%
reduction of their seizures. This finding is consis-
tent with earlier studies using old and new generation
AEDs5, 6. Still, 15% (2 of 13) of these patients discon-
tinued LEV because of irritability occurring within the
first few days of LEV at small doses (500 mg day−1
in two divided doses).
To our knowledge, this is the first reported study us-
ing LEV monotherapy for newly diagnosed epilepsy
patients. Previous work at this centre, as well as the
work of others, has demonstrated successful con-
version to monotherapy in patients with difficult to
control and refractory epilepsy3, 7. However, the ef-
fectiveness of LEV in newly diagnosed cases was not
studied.
These results are important because AEDs ap-
proved for adjunctive therapy may not be effective as
monotherapy8. For example, although gabapentin and
tiagabine demonstrated effectiveness as add-on treat-
ments in refractory partial seizures9–11, monotherapy
trials in newly diagnosed patients failed to show effi-
cacy. These findings would suggest that not all AEDs
approved as an add-on therapy will be effective as
monotherapy for newly diagnosed patients and em-
phasises the need for monotherapy trials. It is also
not clear if any of the new AEDs would be effective
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only as monotherapy for difficult to control and re-
fractory epilepsy patients, but may not show similar
efficacy for the newly diagnosed patients, as has been
previously shown in one study utilising Vigabtrin12.
The small number of patients studied, as well as the
retrospective nature of this study and the short term
of follow-up, may not allow us to make firm conclu-
sions. However, our experience suggests that LEV
can be effective as monotherapy in newly diagnosed
epilepsy patients. Although all of our patients were
female, there is no apparent reason why these results
would not also apply to males. A larger study includ-
ing both sexes with an extended follow-up period is
planned.
Two of our patients experienced irritability that
required discontinuation of the drug. Behavioural
symptoms associated with LEV have been observed
in 13.3% of patients in placebo-controlled epilepsy
trials and to a lesser extent in non-epilepsy trials
utilising LEV monotherapy13. Reports of behavioural
problems during LEV treatment were associated in
patients with a pre-study history of psychiatric prob-
lems. All three patients who reported irritability in
our study had this problem within the first 2 weeks of
LEV therapy at smaller than the recommended start-
ing dosages. Only two of our cohort of patients had a
history of depression prior to starting LEV treatment,
both reported irritability. Our observations, in agree-
ment with the others, suggest that these AEs do not
appear to be dose related13, 14. What makes a minor-
ity of patients susceptible to LEV-related behavioural
side-effects remains to be determined.
In summary, we found that LEV can be effective
as monotherapy in patients with newly diagnosed
epilepsy. In addition, it is very well tolerated with only
a small number of patients discontinuing the drug
due to side-effects. A larger double-blind monother-
apy study for newly diagnosed patients is needed to
confirm our findings.
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